His model was initially very simple but it allowed generation of hypotheses which resulted in experiments that refined the model until today our understanding is sufficiently sophisticated that cardiovascular conditions can be prevented and lives can be prolonged by treating its disorders.
Neither standard volume continuous veno-venous hemofiltration nor high-volume hemofiltration had any effect on blood TNFα or IL-6 levels in a rodent model of prolonged CA treated with CPB.
We sought to assess effects of high-volume and standard volume continuous veno-venous hemofiltration (CVVH) on blood cytokine levels and survival in a rat model of prolonged CA treated with CPB.
In particular, the latency period for tumour appearance was highly prolonged in treated mice, reaching 14 and 18 days, respectively.
Zhan et al. reported a cyclic RGD peptide conjugated PEG PLA micelle for the intracranial gliomas targeted chemotherapy, and the median survival time of mice bearing intracranial U87MG tumor xenografts was significantly prolonged after treated by c RGDyK PEG PLA PTX micelles, suggesting that RGD motif is efficient for targeted drug delivery to integrin αv β3-overexpressed glioblastoma.
Even Ogata et al. acknowledged that their activin treatment, injecting activin RNA into embryos at the 2-cell stage, has a much stronger and prolonged effect than treating isolated blastula-stage blastomeres with a controlled low concentration (5 ng/ml) of activin for 1 hr [2].
This clinical experience suggests that octreotide is effective in treating prolonged or refractory hypoglycaemia induced by SUA, as well as in preventing rebound hypoglycaemia by breaking the vicious circle that can result from glucose supplements and consequent insulin release.
Overall survival was significantly reduced in patients with ECOG 2, alkaline phosphatase ≥1.5 upper limit of normal, lymph node involvement, and significantly prolonged in patients treated with ≥2 docetaxel lines, prior curative therapy, PSA decrease ≥30% with cabazitaxel and in patients treated with abiraterone/enzalutamide after cabazitaxel.
The median survival times were prolonged in mice treated with unencapsulated DXR plus gefitinib (27 weeks) or liposomal DXR plus gefitinib (29.5 weeks) relative to mice treated with either DXR formulation alone (23 and 24 weeks, respectively; Fig. 5B).
Survival was significantly prolonged in animals treated with the FOLFOX-like therapy followed by topotecan (74 days, p=0.0003), which was also significantly longer than animals treated with metronomic topotecan after prior control vehicle treatment (56 days, p=0.0073) or continued FOLFOX-like therapy (46 days, p=0.0003, online supplementary figure 6B).
